ABT · Abbott Laboratories
$93.822026-07-21Sector: Healthcare; Industry: Medical - Devices; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$45
-52.5% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($33 · $45) Analysts Range ($92 · $152) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $40.1B | — | 17.5% | 13.9% | $6.0B | −$3.3B | $2.7B | 6.8% | — | 11.1% | $54.6B | $3.28 | — |
| 2024.Q4 | $40.1B | 0.0% | 17.5% | 0.0% | $13.4B | −$8.9B | $4.5B | 8.0% | — | 23.0% | $61.9B | $3.28 | — |
| 2025.Q1 | $42.0B | 4.6% | 17.7% | 0.0% | $13.7B | −$9.4B | $4.2B | 7.2% | — | 21.8% | $63.4B | $7.67 | — |
| 2025.Q4 | $42.0B | 0.0% | 17.7% | 22.9% | $5.7B | −$668MM | $5.1B | 7.6% | — | 8.9% | $65.5B | $7.67 | — |
| 2026.Q1 | $45.1B | 7.6% | 19.8% | 22.9% | $6.9B | −$20.4B | −$13.5B | 6.9% | — | 9.0% | $87.4B | $3.59 | 18.3 |
| italics below = DCF projection · 10yr Rev CAGR: 7.2% |
| 2027.Q1 | $51.5B | +14.2% | 19.6% | 22.6% | $7.8B | −$10.5B | −$2.7B | 7.8% | −$2.5B | 8.5% | $97.9B | $4.11 | 22.8 |
| 2028.Q1 | $55.9B | +8.5% | 18.9% | 22.3% | $8.2B | −$7.6B | $574MM | 7.8% | $494MM | 8.1% | $105.5B | $4.31 | 21.8 |
| 2029.Q1 | $60.1B | +7.4% | 17.5% | 22.0% | $8.2B | −$7.5B | $669MM | 7.9% | $533MM | 7.5% | $113.1B | $4.31 | 21.8 |
| 2030.Q1 | $64.6B | +7.6% | 21.6% | 21.7% | $10.9B | −$8.0B | $3.0B | 8.0% | $2.2B | 9.3% | $121.0B | $5.73 | 16.4 |
| 2031.Q1 | $69.5B | +7.6% | 21.6% | 21.4% | $11.8B | −$8.6B | $3.2B | 8.1% | $2.2B | 9.4% | $129.6B | $6.19 | 15.2 |
|
| Term. Yr+ | $94.6B | 4.1% | 19.4% | 20.0% | $14.6B | −$7.0B | $7.7B | 8.6% | $77.9B | 8.6% | — | — | — |
Active scenario IV: $45 (-52.5% vs market)